

Evaluation of matrix influence in extractables and leachables analysis of medical device extracts

Samanthi Wickramasekara¹, Keaton Nahan¹, Berk Oktem¹ and Eric M. Sussman¹



¹FDA Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Division of Biology, Chemistry and Materials Science Silver Spring, MD

Plain Language Summary

Accuracy of quantification of extractables and leachables can be reduced by the presence of matrix in the sample. This study is designed to evaluate the extent of the matrix effect in quantifying common polymer additives and explore the feasibility of preparing a suitable matrix matched reference material for the analysis.

Introduction


Background

Extractables and leachables (E&L) are the chemical species that can be released from the device materials to the medium under laboratory and clinical use conditions, respectively. To provide exposure estimate for biocompatibility evaluation, accurate detection and quantification of these E&L are necessary. Liquid chromatography mass spectrometry (LC/MS) is a commonly used analytical technique to identify and semi quantify the nonvolatile extractables in the medium. Matrix effect (ME) occurs when compounds co elute and compete with the ionization of the analyte which can create under/over estimation of the analyte concentration. Occurrence of ME can alter the accuracy, precision and sensitivity of the LC/MS analysis.

Purpose:

This study aims to evaluate the matrix effect in LC/MS analysis of device extracts using different polymer materials and extraction conditions. Additionally, the extract stability will be tested to determine the feasibility of developing a matrix matched reference standard.

Experimental Workflow



LC/UV/MS Parameters

Parameter	Value
Column	Stable Bond C ₁₈ Poroshell 300 columns with 2.1 mm x 100 mm and 2.7 μm particles
LC buffers	<ul style="list-style-type: none"> ESI(+): 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) ESI(-): 10 mM ammonium acetate in water (A) and acetonitrile (B)
Gradient	40%B from 0.0-2.0 min, 100%B at 10 min and hold until 18.3 min (at 0.55 mL/min)
Mass range (m/z)	100-1700
Diode array detector (DAD)	200-600 nm (280 nm for qualitative analysis)
LC/MS libraries	<ul style="list-style-type: none"> DSSTox: Extracted from EPA DSSTox (>100,000 compounds consisting of organic acids, carbamic acids, and carbamates) Agilent E&L PCDL: ~1000 compounds polymer additive relevant compounds Contaminant List: Literature based list of common contaminants (<1000 compounds)

Results




Figure 1. Base peak chromatograms (BPC's) for spiked device extracts (left) ethanol water (EW) extracts and IPA extracts (right) in ESI(+).

Table 1: Identification/quantification of top 5 extractables in the extract mixture (all material extracts mixed at 1:1 ratio) [EW: 1:1 Ethanol:water; IPA: Isopropyl alcohol]

Name	RT (min)	Extract Mixture	Ionization	Average Concentration (mg/kg)	%RSD
Oleamide	9.0	EW	(+)	6	3
Palmitamide	10.0		(+)	22	2
20-amino-3,6,9,12,15,18-hexaoxaicosan-1-yl)carbamate	9.9		(+)	101	1
Benzyl[...]carbamate*	14.2	IPA	(+)	103	1
Triton X-100 Reduced N5	8.0		(+)	187	1
Palmitamide	10.0		(+)	92	3
Stearamide	11.3		(+)	108	2
Triton X-100 Reduced N5	8.0		(+)	257	1
Irgafos 168 Phosphate	14.2	EW	(+)	656	1
Didodecyl 3,3'-thiodipropionate	14.3		(+)	730	6
2-Hydroxyethane-1-sulfonic acid	0.5		(-)	222	2
Carbamic acid, [(trimethoxysilyl)methyl]-, methyl ester	0.6		(-)	218	21
(Acetyloxy)-carbamic acid tert-butyl ester	0.8		(-)	263	1
Carbamic acid, octyl ester	0.6	IPA	(-)	352	23
Carbamic acid, dipropylthio-, O-ethyl ester	11.8		(-)	243	7
Octadecyl-4-hydroxyphenylpropionate	11.0		(-)	2310	17
2-methylidenepentadecanoic acid	9.2		(-)	2304	1
Dodecyl 2-methylacrylate	8.9		(-)	1856	2
Cyanox 1790	10.7	EW	(-)	1560	2
Carbamic acid, dipropylthio-, O-ethyl ester	0.5		(-)	1439	6

*Benzyl [(3S,5S,6S,8S)-8-[(3-amino-2,2-dimethyl-3-oxopropyl)carbamoyl]-6-hydroxy-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-2,9-dimethyldecan-5-yl]carbamate




Figure 2: LC/MS Spike and recovery of standard compound mixture added to the material extract mixture (dashed line indicates the expected recovery)

Table 2: LC/UV Spike-and-recovery of standard compound mixture added to the material extract mixture (CE:Co-elution, ND:Not detected)

Spiked Analyte	Retention Time (Min)	Signal	IPA		EW	
			Recovery (%)	%RSD	Recovery (%)	%RSD
BPA	1.77	UV (280 nm)	C.E.	C.E.	C.E.	C.E.
DEP	2.89	UV (280 nm)	114	2	111	<1
DPhP	7.29	UV (280 nm)	111	2	110	1
DBP	7.86	UV (280 nm)	115	1	88	2
STX	8.56	UV (280 nm)	105	<1	121	1
BHT	8.90	UV (280 nm)	106	1	112	4
SA	12.20	UV (280 nm)	N.D.	N.D.	N.D.	N.D.
DEHP	11.57	UV (280 nm)	C.E.	C.E.	C.E.	C.E.
BBOT	11.85	UV (280 nm)	103	<1	105	1
Irganox 1010	13.34	UV (280 nm)	101	5	97	1
Irganox 1330	13.60	UV (280 nm)	114	8	109	1

Discussion and Conclusion

- Device materials produced different extractables profiles, which provided a complex matrix when combined
- Multiple databases were used to identify these compounds including DSS-TOX
- LC/UV spike and recovery (accuracy and precision) was improved in the absence of the internal standards. Internal standards did not improve compound recovery in the presence of matrix from the device materials.
- LC/UV was less susceptible to matrix effects compared to LC/MS.
- Depending on the ionization mode and adducts, concentrations of hydrophobic extractables were underestimated by 20 percent or more in matrix.
- Although IPA and EW are sometimes claimed to be equivalent semi-polar solvents, they produced non-equivalent recoveries for the spiked samples.

Acknowledgements

This research was funded in part by CDRH Critical Path initiative and an appointment to the Research Participation Program administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy and the U.S. FDA.

Disclaimer: The findings and conclusions in this presentation have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any agency determination or policy. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by Department of Health and Human Services.